Venetoclax Plus Zanubrutinib for the Treatment of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase II trial tests the effect of venetoclax in combination with standard of care (SOC) zanubrutinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells by blocking Bcl-2, a protein needed for cancer cell survival. Zanubrutinib blocks a protein called Bruton tyrosine kinase (BTK), which may help keep cancer cells from growing. It is a type of tyrosine kinase inhibitor. Giving venetoclax in combination with SOC zanubrutinib may be safe and tolerable and may reduce the number of cancer cells that remain in the body in patients with CLL or SLL that have not previously received treatment or at least two years have passed since completing initial treatment.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Potwierdzona diagnoza białaczki limfocytowej (CLL) lub chłoniaka limfocytowego (SLL)
- •Wiek 18 lat lub więcej
- •Lekarz uzna, że pacjent potrzebuje rozpoczęcia leczenia
- •Pacjenci nieleczeni wcześniej (grupa pierwsza) lub leczeni przed co najmniej 2 laty (grupa druga)
- •Pacjenci z grupy drugiej muszą mieć historię wcześniejszego leczenia venetoclaxem w połączeniu z innymi lekami
- •Stan ogólny pacjenta pozwalający na leczenie (ECOG 0-2)
- •Wystarczająca liczba neutrofili (białych krwinek) powyżej 1000/mm³
- •Liczba płytek krwi powyżej 30 000/mm³
✗ Disqualifies
- •Pacjenci leczeni wcześniej innymi inhibitorami BTK (oprócz ibrutinibu) z powodu nietolerancji
- •Pacjenci, którzy przerwali wcześniejsze leczenie venetoclaxem z powodu nietolerancji
- •Więcej niż jedno poprzednie leczenie białaczki (rituximab na ITP lub AIHA się nie liczy)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- August 31, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
Ohio State University Comprehensive Cancer Center
Columbus, United States
Trial contact
The Ohio State University Comprehensive Cancer Center
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/1/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.